Universiteit Maastricht
- Address
- P Debyelaan 25, 6229 HX Maastricht, The Netherlands
Universiteit Maastricht - Advanced Clinical Research Center
Universiteit Maastricht operates a comprehensive clinical research program focusing on oncology, cardiovascular diseases, and neurological disorders. The center demonstrates particular expertise in innovative cancer therapies, including investigations of novel treatment combinations for vulvar cancer, acute myeloid leukemia, and multiple solid tumors, alongside advanced immunotherapy approaches for breast cancer and hematological malignancies.
- Oncology and hematology: Novel therapeutic combinations for AML, multiple myeloma, breast cancer, renal cell carcinoma, non-small cell lung cancer, and B-cell lymphomas
- Cardiovascular research: Studies on hypertrophic cardiomyopathy, transthyretin amyloidosis with cardiomyopathy, and stroke prevention strategies in young patients
- Neuropsychiatry and pain management: Investigations of brain stimulation for depression, psilocybin therapy for fibromyalgia, and neuromuscular disorders including myotonic dystrophy
- Autoimmune and inflammatory conditions: Clinical trials examining treatments for systemic lupus erythematosus and Crohn's disease
The research center demonstrates a strong commitment to precision medicine, with multiple trials investigating biomarker-driven treatment strategies such as EGFR-mutated lung cancer and NPM1-mutated AML. The institution's portfolio reflects a modern approach to clinical research, combining traditional therapeutic development with innovative modalities including immunotherapy combinations, targeted therapies, and emerging treatments for rare diseases. Their work spans early-phase safety studies through large-scale phase 3 efficacy trials, positioning Universiteit Maastricht as a significant contributor to advancing evidence-based medical practice across multiple therapeutic domains.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1Novo Nordisk A/S1active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novo Nordisk A/S2trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Universiteit Maastricht
lock Showing 1 of 7 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Effect of NNC0487‑0111 on Resting Energy Expenditure Following Weight Loss in Adults with Obesity: Randomized Placebo‑Controlled Trial with Low‑Calorie Diet Comparator | Novo Nordisk A/S | Phase I | Recruiting | Jul 2026 | — |
IMP list
lock Showing 1 of 5 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Montelukast | 2 | Unknown | 2023-05-25 | 2023-05-25 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.